Genetic allergen modification in the development of novel approaches to specific immunotherapy.
Identifieur interne : 002793 ( Main/Exploration ); précédent : 002792; suivant : 002794Genetic allergen modification in the development of novel approaches to specific immunotherapy.
Auteurs : S. Mutschlechner [Autriche] ; S. Deifl ; B. BohleSource :
- Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [ 1365-2222 ] ; 2009.
Descripteurs français
- KwdFr :
- Allergènes (génétique), Allergènes (immunologie), Allergènes (usage thérapeutique), Animaux, Clonage moléculaire, Humains, Hypersensibilité (), Hypersensibilité (immunologie), Immunoglobuline E (immunologie), Immunothérapie, Lymphocytes auxiliaires Th2 (immunologie), Protéines de fusion recombinantes (génétique), Protéines de fusion recombinantes (immunologie), Protéines de fusion recombinantes (usage thérapeutique), Vaccins synthétiques (génétique), Vaccins synthétiques (immunologie), Vaccins synthétiques (usage thérapeutique).
- MESH :
- génétique : Allergènes, Protéines de fusion recombinantes, Vaccins synthétiques.
- immunologie : Allergènes, Hypersensibilité, Immunoglobuline E, Lymphocytes auxiliaires Th2, Protéines de fusion recombinantes, Vaccins synthétiques.
- usage thérapeutique : Allergènes, Protéines de fusion recombinantes, Vaccins synthétiques.
- Animaux, Clonage moléculaire, Humains, Hypersensibilité, Immunothérapie.
English descriptors
- KwdEn :
- Allergens (genetics), Allergens (immunology), Allergens (therapeutic use), Animals, Cloning, Molecular, Humans, Hypersensitivity (immunology), Hypersensitivity (therapy), Immunoglobulin E (immunology), Immunotherapy, Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), Recombinant Fusion Proteins (therapeutic use), Th2 Cells (immunology), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Vaccines, Synthetic (therapeutic use).
- MESH :
- chemical , genetics : Allergens, Recombinant Fusion Proteins, Vaccines, Synthetic.
- chemical , immunology : Allergens, Immunoglobulin E, Recombinant Fusion Proteins, Vaccines, Synthetic.
- chemical , therapeutic use : Allergens, Recombinant Fusion Proteins, Vaccines, Synthetic.
- immunology : Hypersensitivity, Th2 Cells.
- therapy : Hypersensitivity.
- Animals, Cloning, Molecular, Humans, Immunotherapy.
Abstract
In the recent past, multiple allergens from relevant allergen sources have been cloned, sequenced and produced as recombinant proteins. The availability of recombinant allergens with immunological characteristics similar to their natural counterparts has improved the diagnosis of allergic disorders and increased our knowledge of the biochemical, structural and immunological characteristics of proteins with allergenic potential. Moreover, the use of defined recombinant proteins as vaccines substituting currently used total protein extracts from allergen sources may improve specific immunotherapy (SIT) of Type I allergy. In addition to producing well-defined batches of wild-type allergens, the recombinant technology offers the possibility to easily and selectively modify their properties or functions. Diverse modifications of allergens can be genetically engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused with proteins that promote immune responses, which counterregulate the disease-eliciting T-helper type 2-dominated immune response in allergic individuals and may therefore, improve the efficacy of SIT. This review will introduce different concepts of allergen modification using genetic engineering to improve vaccines for SIT of Type I allergy.
DOI: 10.1111/j.1365-2222.2009.03317.x
PubMed: 19624521
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002002
- to stream PubMed, to step Curation: 002002
- to stream PubMed, to step Checkpoint: 001F11
- to stream Ncbi, to step Merge: 000702
- to stream Ncbi, to step Curation: 000702
- to stream Ncbi, to step Checkpoint: 000702
- to stream Main, to step Merge: 002819
- to stream Main, to step Curation: 002793
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Genetic allergen modification in the development of novel approaches to specific immunotherapy.</title><author><name sortKey="Mutschlechner, S" sort="Mutschlechner, S" uniqKey="Mutschlechner S" first="S" last="Mutschlechner">S. Mutschlechner</name><affiliation wicri:level="3"><nlm:affiliation>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Deifl, S" sort="Deifl, S" uniqKey="Deifl S" first="S" last="Deifl">S. Deifl</name></author><author><name sortKey="Bohle, B" sort="Bohle, B" uniqKey="Bohle B" first="B" last="Bohle">B. Bohle</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19624521</idno><idno type="pmid">19624521</idno><idno type="doi">10.1111/j.1365-2222.2009.03317.x</idno><idno type="wicri:Area/PubMed/Corpus">002002</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002002</idno><idno type="wicri:Area/PubMed/Curation">002002</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002002</idno><idno type="wicri:Area/PubMed/Checkpoint">001F11</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F11</idno><idno type="wicri:Area/Ncbi/Merge">000702</idno><idno type="wicri:Area/Ncbi/Curation">000702</idno><idno type="wicri:Area/Ncbi/Checkpoint">000702</idno><idno type="wicri:Area/Main/Merge">002819</idno><idno type="wicri:Area/Main/Curation">002793</idno><idno type="wicri:Area/Main/Exploration">002793</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Genetic allergen modification in the development of novel approaches to specific immunotherapy.</title><author><name sortKey="Mutschlechner, S" sort="Mutschlechner, S" uniqKey="Mutschlechner S" first="S" last="Mutschlechner">S. Mutschlechner</name><affiliation wicri:level="3"><nlm:affiliation>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Deifl, S" sort="Deifl, S" uniqKey="Deifl S" first="S" last="Deifl">S. Deifl</name></author><author><name sortKey="Bohle, B" sort="Bohle, B" uniqKey="Bohle B" first="B" last="Bohle">B. Bohle</name></author></analytic><series><title level="j">Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</title><idno type="eISSN">1365-2222</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allergens (genetics)</term><term>Allergens (immunology)</term><term>Allergens (therapeutic use)</term><term>Animals</term><term>Cloning, Molecular</term><term>Humans</term><term>Hypersensitivity (immunology)</term><term>Hypersensitivity (therapy)</term><term>Immunoglobulin E (immunology)</term><term>Immunotherapy</term><term>Recombinant Fusion Proteins (genetics)</term><term>Recombinant Fusion Proteins (immunology)</term><term>Recombinant Fusion Proteins (therapeutic use)</term><term>Th2 Cells (immunology)</term><term>Vaccines, Synthetic (genetics)</term><term>Vaccines, Synthetic (immunology)</term><term>Vaccines, Synthetic (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allergènes (génétique)</term><term>Allergènes (immunologie)</term><term>Allergènes (usage thérapeutique)</term><term>Animaux</term><term>Clonage moléculaire</term><term>Humains</term><term>Hypersensibilité ()</term><term>Hypersensibilité (immunologie)</term><term>Immunoglobuline E (immunologie)</term><term>Immunothérapie</term><term>Lymphocytes auxiliaires Th2 (immunologie)</term><term>Protéines de fusion recombinantes (génétique)</term><term>Protéines de fusion recombinantes (immunologie)</term><term>Protéines de fusion recombinantes (usage thérapeutique)</term><term>Vaccins synthétiques (génétique)</term><term>Vaccins synthétiques (immunologie)</term><term>Vaccins synthétiques (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Allergens</term><term>Recombinant Fusion Proteins</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Allergens</term><term>Immunoglobulin E</term><term>Recombinant Fusion Proteins</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Allergens</term><term>Recombinant Fusion Proteins</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Allergènes</term><term>Protéines de fusion recombinantes</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Allergènes</term><term>Hypersensibilité</term><term>Immunoglobuline E</term><term>Lymphocytes auxiliaires Th2</term><term>Protéines de fusion recombinantes</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hypersensitivity</term><term>Th2 Cells</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hypersensitivity</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Allergènes</term><term>Protéines de fusion recombinantes</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cloning, Molecular</term><term>Humans</term><term>Immunotherapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Clonage moléculaire</term><term>Humains</term><term>Hypersensibilité</term><term>Immunothérapie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the recent past, multiple allergens from relevant allergen sources have been cloned, sequenced and produced as recombinant proteins. The availability of recombinant allergens with immunological characteristics similar to their natural counterparts has improved the diagnosis of allergic disorders and increased our knowledge of the biochemical, structural and immunological characteristics of proteins with allergenic potential. Moreover, the use of defined recombinant proteins as vaccines substituting currently used total protein extracts from allergen sources may improve specific immunotherapy (SIT) of Type I allergy. In addition to producing well-defined batches of wild-type allergens, the recombinant technology offers the possibility to easily and selectively modify their properties or functions. Diverse modifications of allergens can be genetically engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused with proteins that promote immune responses, which counterregulate the disease-eliciting T-helper type 2-dominated immune response in allergic individuals and may therefore, improve the efficacy of SIT. This review will introduce different concepts of allergen modification using genetic engineering to improve vaccines for SIT of Type I allergy.</div></front></TEI><affiliations><list><country><li>Autriche</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Vienne (Autriche)</li></settlement></list><tree><noCountry><name sortKey="Bohle, B" sort="Bohle, B" uniqKey="Bohle B" first="B" last="Bohle">B. Bohle</name><name sortKey="Deifl, S" sort="Deifl, S" uniqKey="Deifl S" first="S" last="Deifl">S. Deifl</name></noCountry><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Mutschlechner, S" sort="Mutschlechner, S" uniqKey="Mutschlechner S" first="S" last="Mutschlechner">S. Mutschlechner</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002793 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002793 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19624521
|texte= Genetic allergen modification in the development of novel approaches to specific immunotherapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19624521" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |